Details of the Active Pharmaceutical Ingredient (API)
General Information of API (ID: D00438) | |||||
---|---|---|---|---|---|
Name |
Minoxidil
|
||||
Synonyms |
Click to Show/Hide the Synonyms of This API
minoxidil; 38304-91-5; Rogaine; Loniten; Regaine; Minoximen; Theroxidil; Lonolox; U-10858; 6-(1-Piperidinyl)-2,4-pyrimidinediamine 3-oxide; 2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide; C9H15N5O; 3-hydroxy-2-imino-6-piperidin-1-ylpyrimidin-4-amine; CHEBI:6942; 6-(piperidin-1-yl)pyrimidine-2,4-diamine 3-oxide; Tricoxidil; 6-Amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine; Alopexil; Alostil; MFCD00063409; Minodyl; MLS000028566; Normoxidil; CHEMBL1372483; 6-(1-piperidinyl)-2,4-pyrimidinediamine-3-oxide; Minossidile [Italian]; Minoxidilum [INN-Latin]; NCGC00015673-08; Minoxidilum; SMR000058963; CAS-38304-91-5; Apo-Gain; DSSTox_CID_20685; DSSTox_RID_79541; 6-Piperidin-1-ylpyrimidine-2,4-diamine 3-oxide; DSSTox_GSID_40685; 2,6-diamino-4-(piperidin-1-yl)pyrimidin-1-ium-1-olate; Neoxidil; Avacor and Mintop; 2,6-diamino-4-piperidylpyrimidin-1-ol; SMR000326812; Loniten (TN); Rogaine (TN); Riup (TN); 2,4-Diamino-6-piperidinopyrimidine 3-oxide; SR-01000075331; SR-05000001479; 3-oxido-6-piperidin-1-ylpyrimidin-3-ium-2,4-diamine; U-10,858; Kopdil; Regaine For Men; Minoxidil,(S); Regaine For Women; UNII-5965120SH1; Prestwick_521; 3-hydroxy-2-imino-6-(1-piperidyl)pyrimidin-4-amine; TM-160; Men''''s Rogaine; Women''''s rogaine; 6-amino-2-imino-4-(piperidin-1-yl)pyrimidin-1(2H)-ol; Rogaine Extra Strength; pyrimidin-1(2H)-ol; Spectrum_000969; Tocris-0583; Minoxidil Extra Strength; regid855572; Opera_ID_1150; Prestwick0_000020; Prestwick1_000020; Prestwick2_000020; Prestwick3_000020; Spectrum2_001053; Spectrum3_000509; Spectrum4_000063; Spectrum5_001299; Lopac-M-4145; CHEMBL802; M 4145; Minoxidil (JAN/USP/INN); CBiol_001798; Lopac0_000786; SCHEMBL29698; BSPBio_000059; BSPBio_001385; BSPBio_002037; KBioGR_000105; KBioGR_000585; KBioSS_000105; KBioSS_001449; MLS000859953; MLS001077294; DivK1c_000160; SCHEMBL232565; SPECTRUM1500415; SPBio_001006; SPBio_001980; BPBio1_000065; CHEMBL609587; GTPL4254; Minoxidil, >=99% (TLC); SGCUT00112; ZINC1735; DTXSID9040685; BCBcMAP01_000193; BDBM81463; CHEBI:92128; HMS500H22; KBio1_000160; KBio2_000105; KBio2_001449; KBio2_002673; KBio2_004017; KBio2_005241; KBio2_006585; KBio3_000209; KBio3_000210; KBio3_001537; NINDS_000160; BCPP000162; Bio1_000084; Bio1_000573; Bio1_001062; Bio2_000105; Bio2_000585; HMS1361F07; HMS1568C21; HMS1791F07; HMS1920P03; HMS1989F07; HMS2089L08; HMS2091F20; HMS2095C21; HMS2233E04; HMS2235N21; HMS3259P21; HMS3262M14; HMS3266O06; HMS3371E15; HMS3372M19; HMS3402F07; HMS3411G16; HMS3675G16; HMS3712C21; Pharmakon1600-01500415; ACT04612; BCP01409; CAS_4201; HY-B0112; NSC_4201; to_000070; ZINC6507066; Tox21_110193; Tox21_500786; 3853AH; BDBM50237593; CCG-40112; NSC757106; SBB056986; STL453211; AKOS015920078; AKOS016339636; Tox21_110193_1; 6-amino-2-imino-4-(piperidin-1-yl); AC-5271; BCP9000929; CCG-220020; CS-1867; DB00350; GS-3605; KS-5164; LP00786; NC00686; NSC-757106; SDCCGSBI-0050764.P005; IDI1_000160; IDI1_033855; SMP1_000192; NCGC00015673-01; NCGC00015673-02; NCGC00015673-03; NCGC00015673-04; NCGC00015673-05; NCGC00015673-06; NCGC00015673-07; NCGC00015673-09; NCGC00015673-10; NCGC00015673-11; NCGC00015673-13; NCGC00015673-20; NCGC00018278-01; NCGC00018278-02; NCGC00018278-03; NCGC00018278-04; NCGC00024666-01; NCGC00024666-02; NCGC00024666-03; NCGC00024666-04; NCGC00024666-05; NCGC00024666-06; NCGC00024666-07; NCGC00024666-08; NCGC00179672-01; NCGC00261471-01; BR-49175; SBI-0050764.P004; AB0013244; AB0093459; 2,6-Diamino-4-piperidinopyrimidine 1-Oxide; 5965120SH1; AB00513797; EU-0100786; FT-0620793; ST50993884; D00418; J10235; M-7481; U10858; 6-(1-Piperidinyl)-2,4-pyrimidinediamine3-oxide; AB00052047-08; AB00052047_09; AB00052047_10; AB00513797-02; NC1=CC(=N/C(/N1O)=N/[H])N1CCCCC1; 102666-EP2272841A1; 102666-EP2281816A1; 102666-EP2301936A1; 304M915; A824098; Q424165; 2,4-diamino-6-(1-piperidinyl)-pyrimidine-3-oxide; Q-201408; SR-01000075331-1; SR-01000075331-3; SR-01000075331-5; SR-05000001479-1; SR-05000001479-2; 3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine; BRD-K06902185-001-05-2; BRD-K06902185-001-10-2; BRD-K14888893-001-02-3; Minoxidil, British Pharmacopoeia (BP) Reference Standard; Z1541638524; Minoxidil, European Pharmacopoeia (EP) Reference Standard; 2-azanylidene-3-oxidanyl-6-piperidin-1-yl-pyrimidin-4-amine; 6-amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidino-pyrimidine; Minoxidil, United States Pharmacopeia (USP) Reference Standard; 6-amino-2-imino-4-(piperidin-1-yl)-1,2-dihydropyrimidin-1-ol; Minoxidil for system suitability, European Pharmacopoeia (EP) Reference Standard
|
||||
Clinical Status |
Approved
|
||||
Disease Indication | Essential hypertension | ICD-11: BA00 | [1] | ||
PubChem CID | |||||
Formula |
C9H15N5O
|
||||
Canonical SMILES |
C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O
|
||||
InChI |
1S/C9H15N5O/c10-7-6-8(12-9(11)14(7)15)13-4-2-1-3-5-13/h6,11,15H,1-5,10H2
|
||||
InChIKey |
ZIMGGGWCDYVHOY-UHFFFAOYSA-N
|
||||
Click to Show/Hide the Molecular Data (Structure/Property) of This API | |||||
Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=4201"></iframe>
|
||||
3D MOL | 2D MOL | ||||
Physicochemical Properties | Molecular Weight | 209.25 | Topological Polar Surface Area | 88.9 | |
XlogP | 1.2 | Complexity | 329 | ||
Heavy Atom Count | 15 | Rotatable Bond Count | 1 | ||
Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 3 | ||
Full List of Drug Formulations (DFMs) Containing This API | ||||||
---|---|---|---|---|---|---|
Minoxidil 10 mg tablet | Click to Show/Hide the Full List of Formulation(s): 4 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Anhydrous lactose; Sodium benzoate; Docusate sodium; Magnesium stearate; Cellulose, microcrystalline; Sodium starch glycolate type a potato
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Actavis Pharma; Carilion Materials Management; Physicians Total Care | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium benzoate | DIG Info | Carbonic anhydrase II (Ki = 30000 nM) | [2] | |||
Docusate sodium | DIG Info | Solute carrier SLCO2B1 (Ki = 2.3 uM) | [3] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Drug Formulation 2 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Anhydrous lactose; Magnesium stearate; Silicon dioxide; Cellulose, microcrystalline; Sodium starch glycolate type a potato
|
|||||
Dosage Form | Oral Tablet | |||||
Company | AvKARE | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Drug Formulation 3 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Anhydrous lactose; Magnesium stearate; Silicon dioxide; Cellulose, microcrystalline; Starch, corn
|
|||||
Dosage Form | Oral Tablet | |||||
Company | A-S Medication Solutions; American Health Packaging; Par Pharmaceutical | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Drug Formulation 4 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Anhydrous lactose; Magnesium stearate; Cellulose, microcrystalline; Colloidal silicon dioxide; Starch, corn
|
|||||
Dosage Form | Oral Tablet | |||||
Company | RemedyRepack; State of Florida DOH Central Pharmacy | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Minoxidil 2.5 mg tablet | Click to Show/Hide the Full List of Formulation(s): 4 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Anhydrous lactose; Sodium benzoate; Docusate sodium; Magnesium stearate; Cellulose, microcrystalline; Sodium starch glycolate type a potato
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Actavis Pharma; Physicians Total Care | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium benzoate | DIG Info | Carbonic anhydrase II (Ki = 30000 nM) | [2] | |||
Docusate sodium | DIG Info | Solute carrier SLCO2B1 (Ki = 2.3 uM) | [3] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Drug Formulation 2 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Anhydrous lactose; Magnesium stearate; Silicon dioxide; Cellulose, microcrystalline; Sodium starch glycolate type a potato
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Aphena Pharma Solutions-Tennessee; AvKARE | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Drug Formulation 3 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Anhydrous lactose; Magnesium stearate; Silicon dioxide; Cellulose, microcrystalline; Starch, corn
|
|||||
Dosage Form | Oral Tablet | |||||
Company | American Health Packaging; Cardinal Health; Par Pharmaceutical; RemedyRepack | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Drug Formulation 4 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Anhydrous lactose; Magnesium stearate; Cellulose, microcrystalline; Colloidal silicon dioxide; Starch, corn
|
|||||
Dosage Form | Oral Tablet | |||||
Company | NCS HealthCare of KY, Inc dba Vangard Labs | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.